A Phase 2 interventional study of NW-3509A and Placebo in Chronic Schizophrenia, sponsored by Newron Pharmaceuticals SPA. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-14.
Sponsored by Newron Pharmaceuticals SPA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Schizophrenia with a site in India — 13 open to participants now, 14 under way, 2 of them phase 3. Schizophrenia · India.
Among the 78 studies in Schizophrenia with a site in India, this one is the 52nd largest by enrollment of the 76 interventional ones that give a count, is the only one that started in 2015, is one of 12 in phase 2, and was the 49th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →13 of the 78 studies in Schizophrenia with a site in India are open now. Recruiting first, the newest first:
Anxo Pharmaceutical Co., Ltd. · Sites in India
Ages 18–65
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in India, United States, Australia and 8 more countries
Ages 5–17
Eli Lilly and Company · Sites in India, United States, Argentina and 4 more countries
Ages 18–55
Newron Pharmaceuticals SPA · Sites in India, United States, Argentina and 2 more countries
Ages 18+
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 35 · Phase 4 10
First in 2003; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 201 across the 76 interventional studies, 333 across the 1 observational. Of the 63 that completed or were terminated, 32 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 78 have an industry lead sponsor. The 10 most frequent:
Newron Pharmaceuticals SPA is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
Newron Pharmaceuticals SPA has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
4 of the studies in Schizophrenia with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
| NCT07939347King's College LondonAVATAR Therapy for Distressing Voices in India and Ethiopia | 2027-09-30 |
| NCT07410507Eli Lilly and CompanyA Study of Brenipatide in Adult Participants With Schizophrenia | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 78 studies in Schizophrenia with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or risperidone). NW-3509A is given as an oral dose range of 15 to 25 mg, BID in a 1:1 ratio.
This is a prospective, 4-week, randomized, double-blind, placebo-controlled, study designed to evaluate the safety, tolerability, and preliminary efficacy of an oral dose range of NW-3509A of 30 to 50 mg/day (15 to 25 mg, BID) in patients with chronic schizophrenia on a stable dose of an antipsychotic (aripiprazole or risperidone). A minimum of 90 patients will be randomized in a 1:1 ratio to receive either NW-3509A (n=45) or placebo (n=45). Dose increases will be performed only during in-patient setting.
Safety and efficacy assessments will be done on a weekly basis during the randomized treatment period. The assessment of safety will be based on laboratory tests (biochemistry, hematology, and urinalysis), 12-lead standard ECG, vital signs, physical examinations, neurological examinations, C-SSRS, ESRS-A, subjective reporting of any AE by the subject, objective observation of any AE by the Investigator. Pharmacokinetic samples will be taken at various time-points. Efficacy assessments will include the PANSS, CGI-C, CGI-S and the Strauss-Carpenter Level of Functioning (LOF) scale.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
Drug: NW-3509A
Patients will receive matching placebo BID
Drug: Placebo
Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
Patients will be given oral dose of matching Placebo
To evaluate the safety and tolerability of NW-3509A in patients with schizophrenia on a stable dose of their current antipsychotic medication (aripiprazole or risperidone).
To evaluate the safety and tolerability of NW-3509A given as an oral dose range of 30 to 50 mg/day (15 to 25 mg, BID) in patients with schizophrenia on a stable dose of their current antipsychotic medication (aripiprazole or risperidone).
Time frame: 27 days
Assessment of Positive and Negative Syndrome Scale (PANSS)
Assessment of the PANSS - a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control, will be carried out at every visit
Time frame: 27 days
Assessment of CGI-S (severity) and CGI-C (change)
Measure of change from baseline will be done at every assessment
Time frame: 27 days; change from baseline
Assessment of Strauss-Carpenter Level of Functioning (LOF) scale
The LOF scale will be used at baseline and end of study, to evaluate the clinical outcome
Time frame: 27 days; baseline and end of study
Measurement of plasma concentration Cmax
Blood samples will be collected for PK evaluation at time points
Time frame: 27 days
Plan to share: No
Ran from Dec 2015 to primary completion in Dec 2016, 12 months.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 12 months is below that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.